2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

908. Outcomes Research: Myeloid Malignancies: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Vaccines, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Natural Language Processing, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, APL, MDS, MPN, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6349 GLP-1 receptor agonists are associated with reduced mortality in essential thrombocythemia

Esteban Toro Velez, MD, Carolina Velez-Mejia, MD2, Erin McDevitt, MD3, Ruchi Desai, MD4
1 Virginia Commonwealth University, Richmond, Virginia, United States
2 Virginia Commonwealth University, Richmond, Virginia, United States
3 Virginia Commonwealth University, Richmond, Virginia, United States
4 Virginia Commonwealth University, Richmond, Virginia, United States

Background:

Essential Thrombocytosis (ET) is a clonal myeloid neoplasm characterized by megakaryocytic proliferation, platelet hyperreactivity, and a chronic pro-inflammatory microenvironment. Chronic exposure to inflammatory cytokines perpetuates the malignant clone and causes micro and macro vascular complications. Glucagon-like peptide-1 receptor agonists (GLP1) reduces systemic inflammation and is currently under investigation to be implemented as adjuvant treatment for multiple oncologic malignancies. To our knowledge, this study represents the first large-scale real-world analysis investigating the impact of GLP1 RA therapy on survival outcomes in patients with ET.

 

Methods:

A retrospective cohort study using the TriNetX Research Network from 153 healthcare organizations from the Global Collaborative Network was carried out. We included patients ≥ 18 years diagnosed with ET using the ICD-10 code between January 01, 2005 to June 30, 2026 who received systemic therapy including hydroxyurea, interferon alpha 2a/2b, ropeginterefon alpha-2b or anagrelide. After the diagnosis and starting appropriate treatment, patients were divided into whether they received a GLP1 or not. The only variable different among comparison groups was the presence or absence of the GLP1. Cohorts were balanced using propensity score matching for age at diagnosis, female, Black race, Hispanics, hemoglobin, platelet count, body mass index, comorbidities, and concomitant medications. Kaplan-Meier survival curves were used to assess overall survival (OS) over a 10 year follow up period.

 

Results:

A total of 21,499 patients were identified, of these 686 patients started GLP1 after the diagnosis and 20,807 were not on GLP1. After balancing each cohort had a total of 686 patients.

 

Patients with ET who were taking a GLP1 had better OS than those who did not [p-value of <0.0001, HR 0.344, CI 0.247,0.479]. At 10 years the median overall survival for both groups was not reached, however, the survival probability was noted to be 81%% vs 64%, respectively.

 

The risk for developing thromboembolic complications had a tendency to be less in those taking GLP1, however, this was not yet statistically significant (10% vs 12%, HR 0.808 CI 0.575,1.135). No difference was seen in the risk for bleeding or myelofibrosis among both groups.

 

Conclusions:

GLP1 therapy was associated with better OS in patients with ET. Although reductions in thromboembolic events did not reach statistical significance and database limitations preclude establishing the disease-specific mortality, these findings suggest a significant survival benefit of GLP1. This could be explained as the immunomodulatory effect of GLP1 may create a favorable hematopoietic microenvironment and slow the clonal evolution. Therefore, prospective clinical trials are needed to confirm these biologic events in patients with ET and potentially establish GLP1 as an adjuvant treatment in cancer care.

Esteban Toro Velez, MD: No relevant conflicts of interest to declare.